Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA Contract Liabilities

Contract Liabilities at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0—
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$12.65M+644%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$10.42M—
Mannkind logo
MannkindMNKD
$36.86M-18.9%
PTH
Pelthos TherapeuticsPTHS
$1.03M—
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$14.31M-21.5%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+145%
Enterprise value$5.8B+157%
P/E74×-436×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemJune 30, 2026December 31, 2025
Other current liabilities20,05222,134
Total current liabilities171,247139,184
Non-current liabilities:
Non-current deferred revenue31,81131,811
Non-current operating lease liabilities4,8856,510
Other long-term liabilities34,01818,522
Total liabilities241,961196,027
Commitments and contingencies (Note 13)

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's contract liabilities?
Kiniksa Pharmaceuticals International, plc (KNSA) reported contract liabilities of $31.81M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's contract liabilities changed year-over-year?
Kiniksa Pharmaceuticals International, plc's contract liabilities decreased by 0.0% year-over-year, from $31.81M to $31.81M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's contract liabilities?
Over 3 years (2022 to 2025), Kiniksa Pharmaceuticals International, plc's contract liabilities has grown at a 38.4% compound annual growth rate (CAGR), from $12M to $31.81M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.

Ask your AI about Kiniksa Pharmaceuticals International, plc's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude